常染色体显性阿尔茨海默病中淀粉样β负荷的变异依赖性异质性:一项观察性研究的横断面和纵向分析
该研究对DIAN观察性研究中340名参与者(206名致病突变携带者,134名非携带者)进行横断面和纵向分析,发现尽管临床痴呆评定量表进展相似(p>0.7),但皮质和纹状体PiB-PET信号在PSEN1、PSEN2或APP不同致病变异间存在显著差异(p<0.0001),而脑脊液Aβ42水平无显著差异(密码子分组p=0.49;结构域分组p=0.095)。作者认为PiB-PET信号升高不一定反映更严重或更晚期的疾病,脑脊液和PET的Aβ测量不可互换。
要点
- 常染色体显性阿尔茨海默病中,不同致病变异间PiB-PET信号存在显著异质性(p<0.0001)。
- 尽管PiB-PET信号差异显著,临床痴呆评定量表进展相似(p>0.7)。
- 脑脊液Aβ42水平在密码子分组(p=0.49)和结构域分组(p=0.095)间无显著差异。
核心结论
- 常染色体显性阿尔茨海默病致病变异呈现高度差异化的PiB-PET信号时间和区域模式,尽管功能进展相似。
- 个体水平较高的PiB-PET信号可能不反映更严重或更晚期的疾病。
- 脑脊液和PET的Aβ测量不可互换,可能反映不同的Aβ驱动病理生物学过程。
研究设计与样本
- 对DIAN观察性研究数据进行横断面和纵向分析,纳入2008年9月至2019年6月期间入组的340名18岁及以上、家族中有常染色体显性阿尔茨海默病病史的参与者。
- 206名为PSEN1、PSEN2或APP致病突变携带者,134名为非携带者,共识别62种独特致病变异。
- 变异按两种方式分组:按受影响蛋白结构域分组;PSEN1变异按密码子200前后位置分组。
- 检查Aβ生物标志物变异依赖性变异性,包括匹兹堡化合物B PET(PiB-PET)信号、脑脊液Aβ1-42(Aβ42)水平和Aβ1-40(Aβ40)水平。
主要发现
- 皮质和纹状体PiB-PET信号在两种分组方式下均显示显著的变异依赖性变异性(p<0.0001)。
- 临床痴呆评定量表进展相似(p>0.7)。
- 脑脊液Aβ42水平在密码子分组(p=0.49)和结构域分组(p=0.095)间无显著差异。
- 纵向PiB-PET信号在密码子分组间也存在差异,与横断面分析一致。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Insights gained from studying individuals with autosomal dominant Alzheimer's disease have broadly influenced mechanistic hypotheses, biomarker development, and clinical trials in both sporadic and dominantly inherited Alzheimer's disease. Although pathogenic variants causing autosomal dominant Alzheimer's disease are highly penetrant, there is substantial heterogeneity in levels of amyloid β (Aβ) between individuals. We aimed to examine whether this heterogeneity is related to disease progression and to investigate the association with mutation location within PSEN1, PSEN2, or APP. METHODS: We did cross-sectional and longitudinal analyses of data from the Dominantly Inherited Alzheimer's Network (DIAN) observational study, which enrols individuals from families affected by autosomal dominant Alzheimer's disease. 340 participants in the DIAN study who were aged 18 years or older, had a history of autosomal dominant Alzheimer's disease in their family, and who were enrolled between September, 2008, and June, 2019, were included in our analysis. 206 participants were carriers of pathogenic mutations in PSEN1, PSEN2, or APP, and 134 were non-carriers. 62 unique pathogenic variants were identified in the cohort and were grouped in two ways. First, we sorted variants in PSEN1, PSEN2, or APP by the affected protein domain. Second, we divided PSEN1 variants according to position before or after codon 200. We examined variant-dependent variability in Aβ biomarkers, specifically Pittsburgh-Compound-B PET (PiB-PET) signal, levels of CSF Aβ1-42 (Aβ42), and levels of Aβ1-40 (Aβ40). FINDINGS: Cortical and striatal PiB-PET signal showed striking variant-dependent variability using both grouping approaches (p<0·0001), despite similar progression on the clinical dementia rating (p>0·7), and CSF Aβ42 levels (codon-based grouping: p=0·49; domain-based grouping: p=0·095). Longitudinal PiB-PET signal also varied across codon-based groups, mirroring cross-sectional analyses. INTERPRETATION: Autosomal dominant Alzheimer's disease pathogenic variants showed highly differential temporal and regional patterns of PiB-PET signal, despite similar functional progression. These findings suggest that although increased PiB-PET signal is generally seen in autosomal dominant Alzheimer's disease, higher levels of PiB-PET signal at an individual level might not reflect more severe or more advanced disease. Our results have high relevance for ongoing clinical trials in autosomal dominant Alzheimer's disease, including those using Aβ PET as a surrogate marker of disease progression. Additionally, and pertinent to both sporadic and autosomal dominant Alzheimer's disease, our results suggest that CSF and PET measures of Aβ levels are not interchangeable and might reflect different Aβ-driven pathobiological processes. FUNDING: National Institute on Aging, Doris Duke Charitable Foundation, German Center for Neurodegenerative Diseases, Japanese Agency for Medical Research and Development.
引用
- Chhatwal JP, Schultz SA, McDade E, et al. Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurol. 2022. PMID: 35065037. doi:10.1016/S1474-4422(21)00375-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。